The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome

Not Applicable

Completed

• Conditions: IBS
• Interventions: Dietary Supplement: Probiotics; Other: Placebo

• Registration Number: NCT03986476
• Lead Sponsor: Örebro University, Sweden

Brief Summary

This study will investigate the effects of supplementation with two different probiotic products (Lactobacillus reuteri strains) on the intestinal barrier function, gut health and stress symptoms in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients.

Detailed Description

After having given their written informed consent, subjects will complete screening procedures to evaluate their eligibility for the study (visit 1). Study participants will undergo two baseline visits (visits 2 and 3, 3 weeks apart) to account for individual variations, and will then be randomly assigned to 6-week intake of one of two Lactobacillus reuteri strains, or placebo in a ratio of 1:1:1 (stratified by sex). Participants will attend a study visit three weeks into the intervention (visit 4) and at the end of the intervention (visit 5, week 6). The intestinal permeability will be assessed using a standardized multi-sugar test at visit 2, visit 3, visit 4, and at end of intervention (visit 5). Blood, saliva and faecal samples will be collected at visit 2-5. In addition, gastrointestinal symptoms will be recorded at those visits (using Gastrointestinal symptom rating scale-IBS, GSRS-IBS; IBS severity scoring system, IBS- SSS). Quality of life using the 5Q-5D-5L and Hospital Anxiety and Depression Scale (HADS) scores will also be recorded at those visits. In addition, at visit 3 and visit 5, the IBS-Quality of life (IBS-QoL) and the Perceived Stress Scale (PSS) will be completed. In a daily diary, participants will record stool frequency and consistency from visit 2 until end-of-study visit 5. Dietary habits of the patients will be assessed via a food frequency questionnaire (FFQ) and a 3-day food diary before the intervention (between visit 2 and 3).

Study Timeline

• Study Start: 2019-03-26
• Study First Submitted: 2019-06-07
• Study First Submitted QC: 2019-06-13
• Study First Posted: 2019-06-14
• Primary Completion: 2021-05-10
• Study Completion: 2021-05-10
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-08
• Last Update Posted: 2021-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• Signed informed consent
• Fulfilled Rome IV diagnostic criteria for IBS with predominant diarrhoea
• Mild-to-severe IBS symptoms according to the IBS severity scoring system (IBS-SSS; a score of ≥75)
• Age: 18-65 years

Exclusion Criteria

1. Known organic gastrointestinal disease (e.g. inflammatory bowel disease, IBD)
2. Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy
3. History of or present gastrointestinal malignancy or polyposis
4. Recently (within the last 6 months) diagnosed gastrointestinal infection
5. Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
6. Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis)
7. Autoimmune disease and/or patients receiving immunosuppressive medications
8. Chronic pain syndromes (e.g. fibromyalgia)
9. Chronic fatigue syndrome
10. Severe endometriosis
11. Coeliac disease
12. Recently (within the last 3 months) diagnosed lactose intolerance
13. Females who are pregnant or breast-feeding
14. Regular intake of systemic corticosteroids and anti-inflammatory medication (including non-steroidal anti-inflammatory drugs, NSAIDs) during the last 3 months or incidental use in the last 2 weeks prior to randomisation
15. Recent (< 4 weeks) intake of proton pump inhibitors, PPIs (e.g., omeprazol)
16. Use of anti-depressants in the last 3 months
17. Regular oral intake of mast cell stabilising drugs (e.g. sodium cromoglycate) during the last 3 months or incidental use in the last 2 weeks prior to screening
18. Antimicrobial treatment 6 weeks prior to first screening visit
19. Antimicrobial prophylaxis (eg. acne, urinary tract infection)
20. Regular consumption of probiotic products 4 weeks prior to first baseline visit
21. Concurrent or recent (<4 weeks) use of nutritional supplements or herb products affecting intestinal function (e.g. aloe vera, St. John´s Wort, fibres, prebiotics) if the investigator considers those could affect the study outcome.
22. Inability to maintain exercise routine and dietary pattern during the study.
23. Abuse of alcohol or drugs
24. Any clinically significant present or past disease/condition which in the investigator's opinion could interfere with the results of the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lactobacillus reuteri strain 2	Probiotics	Probiotic compound
Lactobacillus reuteri strain 1	Probiotics	Probiotic compound
Placebo	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
Change in small intestinal permeability after 6 weeks (urinary lactulose/rhamnose ratio, 0-5h)	6 weeks	Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 6-week intervention with the probiotic products compared to the placebo product

Secondary Outcome Measures

Name	Time	Method
Change in whole gut permeability after 6 weeks (urinary sucralose/erythritol ratio, 0-24h)	6 weeks	Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Change in whole gut permeability after 3 weeks (urinary sucralose/erythritol excretion ratio, 0-24h)	3 weeks	Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Change in colonic permeability after 6 weeks (urinary sucralose/erythritol ratio, 5-24h)	6 weeks	Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Change in small intestinal permeability after 3 weeks (urinary lactulose/rhamnose ratio, 0-5h)	3 weeks	Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 3-week intervention with the probiotic products compared to the placebo product
Change in gastroduodenal permeability after 3 weeks (urinary sucrose excretion, 0-5hrs)	3 weeks	Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Change in inflammatory status after 3 weeks	3 weeks	Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)
Change in colonic permeability after 3 weeks (urinary sucralose/erythritol ratio, 5-24hrs)	3 weeks	Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Change in gastroduodenal permeability after 6 weeks (urinary sucrose excretion, 0-5hrs)	6 weeks	Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Change in inflammatory status after 6 weeks	6 weeks	Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)

Trial Locations

Locations (1)

Örebro University; 🇸🇪 Örebro, Örebro Län, Sweden